Nootropics and neuroprotective drugs Market Size, Production, Sales, Average Product Price, Market Share, Import vs Export

Nootropics and Neuroprotective Drugs Market: Accelerating Demand Driven by Cognitive Health Awareness

The Nootropics and neuroprotective drugs Market is undergoing a structural transformation as cognitive health moves from a niche medical concern to a mainstream wellness priority. According to Datavagyanik, global demand for cognitive enhancement and neuroprotection therapies has expanded at a steady double-digit trajectory, with consumption volumes rising by nearly 11–13% annually over the past three years. This acceleration is closely linked to demographic expansion in the aging population. For instance, individuals aged 60 and above are increasing at over 3% per year globally, directly influencing prescription volumes for neuroprotective therapies targeting Alzheimer’s disease, Parkinson’s disease, and mild cognitive impairment.

Simultaneously, demand is not limited to geriatric patients. A younger demographic—particularly professionals and students aged 20–40—is driving the preventive and performance-enhancing segment of the Nootropics and neuroprotective drugs Market. For example, cognitive supplements and prescription nootropics have witnessed retail sales growth exceeding 14% annually in developed markets, supported by expanding awareness about productivity optimization and mental resilience. This dual demand dynamic—therapeutic and enhancement-driven—is creating a diversified revenue base for the Nootropics and neuroprotective drugs Market.

Nootropics and Neuroprotective Drugs Market Trends: Shift Toward Preventive Neurology

One of the defining trends shaping the Nootropics and neuroprotective drugs Market is the shift from reactive treatment to preventive neurology. Instead of initiating therapy after significant neurodegeneration, healthcare systems are increasingly focusing on early-stage intervention. For instance, early diagnosis rates of mild cognitive impairment have increased by nearly 18% in high-income countries over the last five years, leading to earlier prescription of neuroprotective agents.

This proactive approach directly expands the patient pool for the Nootropics and neuroprotective drugs Market. Drugs such as cholinesterase inhibitors, NMDA receptor antagonists, and emerging neurotrophic modulators are seeing broader application beyond advanced-stage patients. In addition, the preventive trend is supported by lifestyle integration, where omega-3 derivatives, racetams, and adaptogenic compounds are marketed alongside digital cognitive training platforms. The integration of pharmaceuticals with digital therapeutics, for example, has boosted therapy adherence rates by over 20%, strengthening long-term demand within the Nootropics and neuroprotective drugs Market.

Nootropics and Neuroprotective Drugs Market Drivers: Rising Burden of Neurodegenerative Disorders

The growing incidence of neurodegenerative disorders remains the most powerful growth driver for the Nootropics and neuroprotective drugs Market. Alzheimer’s disease prevalence alone is increasing by nearly 7–8% annually in several developed economies. For instance, patient populations in North America and Western Europe have expanded significantly due to higher life expectancy, which now exceeds 78–82 years in many regions.

Parkinson’s disease cases are projected to nearly double by 2040 in certain countries, directly translating into rising demand for dopamine modulators and neuroprotective compounds. Such epidemiological expansion provides a predictable long-term demand trajectory for the Nootropics and neuroprotective drugs Market. Moreover, post-stroke cognitive impairment affects nearly 30% of stroke survivors, adding another substantial application segment. As stroke incidence remains high—over 12 million new cases annually worldwide—the downstream demand for neuroprotective therapies strengthens further.

Nootropics and Neuroprotective Drugs Market Size Expansion Through R&D Intensification

The Nootropics and neuroprotective drugs Market Size is being significantly influenced by increased R&D investments in central nervous system (CNS) therapies. Pharmaceutical companies have increased CNS-focused R&D expenditure by nearly 9–10% annually over the past five years. For example, late-stage pipelines now include monoclonal antibodies targeting amyloid plaques and tau proteins, alongside mitochondrial stabilizers designed to slow neuronal degeneration.

The expansion of clinical trials in neuroprotection has risen by approximately 15% year-over-year, indicating strong innovation momentum within the Nootropics and neuroprotective drugs Market. Additionally, repurposing strategies are accelerating product launches. Drugs originally developed for epilepsy or attention disorders are being repositioned for broader cognitive enhancement indications, shortening time-to-market and improving commercialization prospects. This innovation-driven momentum is a fundamental pillar supporting the expanding Nootropics and neuroprotective drugs Market Size.

Nootropics and Neuroprotective Drugs Market Growth in Emerging Economies

Emerging economies are becoming critical growth engines for the Nootropics and neuroprotective drugs Market. For instance, Asia-Pacific has witnessed healthcare expenditure growth exceeding 8% annually, enabling wider access to neurological therapies. Countries with rapidly aging populations, such as those in East Asia, are seeing increased diagnosis rates of dementia-related conditions, directly influencing prescription growth.

Urbanization and rising disposable income in middle-income economies are further boosting over-the-counter nootropic sales. For example, e-commerce sales of cognitive supplements in Southeast Asia have grown by over 20% annually, highlighting digital distribution as a growth accelerator. This shift expands the addressable market beyond hospital-centric channels, strengthening retail penetration within the Nootropics and neuroprotective drugs Market.

Nootropics and Neuroprotective Drugs Market: Technological Integration and Biomarker Development

Another transformative trend in the Nootropics and neuroprotective drugs Market is biomarker-driven therapy personalization. Advances in neuroimaging and cerebrospinal fluid biomarkers now enable earlier and more accurate disease detection. For instance, amyloid PET imaging adoption has increased by nearly 12% annually in developed healthcare systems.

This precision diagnostic expansion supports targeted therapy initiation, improving drug efficacy outcomes and enhancing physician confidence in prescribing advanced neuroprotective agents. In parallel, artificial intelligence-driven cognitive assessment tools are being deployed to monitor treatment response, ensuring dose optimization and sustained drug utilization. Such technology integration directly strengthens long-term therapy adherence within the Nootropics and neuroprotective drugs Market.

Nootropics and Neuroprotective Drugs Market Size: Expanding Commercialization Channels

The Nootropics and neuroprotective drugs Market Size is also expanding due to diversified commercialization models. Traditionally dominated by prescription channels, the market now includes nutraceutical hybrids and direct-to-consumer cognitive enhancers. Retail pharmacy networks have reported double-digit growth in cognitive health segments, while online pharmacy platforms have expanded neuroprotective drug sales by nearly 17% annually.

For example, subscription-based cognitive health platforms bundle prescription consultations with supplement delivery, increasing recurring revenue streams. This model reduces patient drop-off and ensures continuity of therapy, directly contributing to revenue stability in the Nootropics and neuroprotective drugs Market.

Nootropics and Neuroprotective Drugs Market Outlook: Long-Term Structural Momentum

The structural drivers underpinning the Nootropics and neuroprotective drugs Market suggest sustained expansion over the next decade. Aging demographics, increasing neurological disease prevalence, early diagnosis adoption, and performance-enhancement demand collectively create a multi-layered growth environment. For instance, workforce productivity pressures in competitive economies are normalizing cognitive enhancement discussions, expanding acceptance beyond clinical boundaries.

Furthermore, government initiatives aimed at dementia management are increasing funding for early screening and treatment programs, indirectly supporting product uptake. With neurodegenerative disorders ranking among the top causes of disability-adjusted life years globally, healthcare systems are allocating larger budget shares to neurological therapeutics.

As a result, the Nootropics and neuroprotective drugs Market Size is expected to maintain strong upward momentum, supported by innovation pipelines, digital integration, and broader consumer awareness. The convergence of pharmaceutical innovation and lifestyle-driven cognitive optimization ensures that the Nootropics and neuroprotective drugs Market remains one of the most dynamic segments within the broader CNS therapeutics landscape.

“Track Country-wise Nootropics and neuroprotective drugs Production and Demand through our Nootropics and neuroprotective drugs Production Database”

• • • Nootropics and neuroprotective drugs production database for 22+ countries worldwide
    • Nootropics and neuroprotective drugs sales volume for 22+ countries
    • Country-wise Nootropics and neuroprotective drugs production capacity and production plant mapping, production capacity utilization for 20+ manufacturers
    • Nootropics and neuroprotective drugs production plants and production plant capacity analysis for top manufacturers

Nootropics and Neuroprotective Drugs Market: North America Driving High-Value Demand

The Nootropics and neuroprotective drugs Market in North America represents the highest revenue concentration globally, supported by advanced diagnostic infrastructure and high per capita healthcare spending exceeding USD 12,000 annually in the United States. Datavagyanik highlights that nearly 6–7 million individuals in the region are currently living with Alzheimer’s disease, with patient numbers expanding at approximately 5% per year. This growing patient base directly sustains prescription volumes of cholinesterase inhibitors, NMDA antagonists, and newly introduced monoclonal therapies within the Nootropics and neuroprotective drugs Market.

For instance, hospital procurement data indicates that neuroprotective injectables have witnessed procurement growth of nearly 12% year-over-year, particularly in tertiary care centers. In addition, cognitive enhancement prescriptions for ADHD and related disorders have expanded by more than 9% annually, broadening the addressable population within the Nootropics and neuroprotective drugs Market. Retail pharmacy penetration, especially through online platforms, has further amplified regional consumption dynamics.

Nootropics and Neuroprotective Drugs Market: Europe’s Aging Population and Structured Reimbursement

Europe constitutes nearly 25–30% of global demand in the Nootropics and neuroprotective drugs Market, supported by an aging demographic where over 21% of the population is aged above 65 years. Countries such as Germany, France, and Italy are witnessing dementia diagnosis rates rising by approximately 6–8% annually. For example, Germany alone reports over 1.5 million dementia patients, directly influencing sustained prescription demand.

Structured reimbursement systems in Western Europe ensure consistent therapy adoption. Neuroprotective drug reimbursement coverage exceeding 70% in several EU healthcare systems enhances accessibility. Consequently, production supply chains targeting Europe emphasize regulatory compliance and high-quality formulations. The Nootropics and neuroprotective drugs Market in Eastern Europe is also expanding, albeit at a faster growth rate of nearly 10–12%, driven by improving healthcare infrastructure and rising awareness.

Nootropics and Neuroprotective Drugs Market: Asia-Pacific as the Fastest Growing Region

Asia-Pacific is emerging as the most dynamic region in the Nootropics and neuroprotective drugs Market, with demand growth exceeding 14% annually. Rapid aging in countries such as Japan and South Korea significantly contributes to therapeutic demand. For instance, Japan’s population aged above 65 exceeds 29%, creating a robust patient base for neurodegenerative disease management.

In parallel, India and China are driving volume growth in generic neuroprotective formulations. Rising healthcare expenditure, which is increasing at 8–10% annually in several Asian economies, directly strengthens purchasing power for neurological therapies. E-commerce channels in Southeast Asia have recorded more than 20% annual growth in cognitive supplement sales, indicating strong consumer-driven expansion within the Nootropics and neuroprotective drugs Market.

Nootropics and Neuroprotective Drugs Market: Production Landscape and Manufacturing Concentration

Production within the Nootropics and neuroprotective drugs Market is concentrated in North America, Europe, India, and China. The United States leads in innovative molecule production, especially monoclonal antibodies and advanced neuroprotective injectables. Meanwhile, India and China dominate generic production, collectively accounting for over 45% of global generic neuroprotective drug exports.

For example, India’s pharmaceutical exports in CNS therapeutics have grown at nearly 11% annually, reflecting manufacturing scale advantages. Active pharmaceutical ingredient (API) manufacturing clusters in China provide cost efficiencies of 20–30% compared to Western facilities. This production geography directly impacts global trade flows within the Nootropics and neuroprotective drugs Market, balancing high-value patented drugs from developed regions with cost-effective generics from Asia.

Nootropics and Neuroprotective Drugs Market Segmentation: By Drug Class and Mechanism

The Nootropics and neuroprotective drugs Market is segmented by cholinesterase inhibitors, NMDA receptor antagonists, dopamine modulators, racetams, neurotrophic agents, and antioxidant-based compounds. Cholinesterase inhibitors continue to command nearly 30% of prescription share due to established efficacy in Alzheimer’s management.

However, neurotrophic and disease-modifying agents are expanding at a faster pace of 15–18% annually, driven by innovation pipelines. For example, monoclonal therapies targeting amyloid aggregation have demonstrated higher price realization and premium reimbursement, strengthening their revenue share in the Nootropics and neuroprotective drugs Market. Meanwhile, racetams and adaptogenic compounds are experiencing steady growth in retail and over-the-counter channels, particularly among younger demographics focused on productivity enhancement.

Nootropics and Neuroprotective Drugs Market Segmentation: By Distribution Channel

Hospital pharmacies account for approximately 45% of revenue in the Nootropics and neuroprotective drugs Market, largely due to injectable biologics and specialized prescriptions. Retail pharmacies contribute around 35%, driven by oral formulations and long-term therapy renewals. Online channels represent the fastest-growing segment, expanding at nearly 18% annually.

For instance, subscription-based medication delivery platforms have improved refill adherence rates by nearly 22%, directly influencing consistent consumption volumes. This distribution diversification enhances revenue resilience within the Nootropics and neuroprotective drugs Market, minimizing dependence on a single channel.

Nootropics and Neuroprotective Drugs Market: Application-Based Demand Dynamics

From an application standpoint, Alzheimer’s disease accounts for nearly 40% of total demand in the Nootropics and neuroprotective drugs Market. Parkinson’s disease contributes approximately 20%, while stroke-related cognitive impairment and traumatic brain injury collectively represent another 15–18%.

For example, post-stroke rehabilitation centers have increased neuroprotective prescriptions by nearly 10% annually, reflecting expanding therapy integration. ADHD and cognitive performance enhancement represent a smaller yet rapidly expanding segment, growing at nearly 12–14% annually. This diversified application base reduces demand volatility and strengthens long-term stability within the Nootropics and neuroprotective drugs Market.

Nootropics and Neuroprotective Drugs Market: Nootropics and Neuroprotective Drugs Price Analysis

The Nootropics and neuroprotective drugs Price structure varies significantly between patented biologics and generic oral formulations. For instance, annual therapy costs for advanced monoclonal treatments can exceed USD 20,000 per patient in developed markets, while generic oral nootropics may cost below USD 500 annually.

The Nootropics and neuroprotective drugs Price Trend for patented drugs has shown moderate upward movement of 3–5% annually due to innovation premiums and regulatory compliance costs. Conversely, the Nootropics and neuroprotective drugs Price for generics has declined by nearly 2–4% per year due to intense competition among manufacturers in India and China.

Raw material costs, particularly for specialized APIs, have also influenced the Nootropics and neuroprotective drugs Price Trend. For example, supply chain disruptions during recent years caused API costs to rise by 8–10%, temporarily pushing up the Nootropics and neuroprotective drugs Price in certain markets. However, improved logistics and localized manufacturing have stabilized the Nootropics and neuroprotective drugs Price Trend over the past year.

Nootropics and Neuroprotective Drugs Market: Regional Price Variations and Trade Impact

Regional disparities in the Nootropics and neuroprotective drugs Price are pronounced. In North America, patented drugs command premium pricing due to strong intellectual property protection and reimbursement coverage. In contrast, Asia-Pacific markets emphasize affordability, leading to competitive pricing strategies and thinner margins.

For example, average annual treatment costs in emerging Asian markets are 40–60% lower compared to the United States, directly influencing trade flows and parallel import dynamics. Currency fluctuations have also shaped the Nootropics and neuroprotective drugs Price Trend, particularly in Latin America where depreciation pressures increased import costs by nearly 6–8% in certain years.

Despite these fluctuations, long-term Nootropics and neuroprotective drugs Price Trend movement indicates gradual stabilization supported by generic penetration and biosimilar development. As biosimilars enter the market, price erosion of 15–20% is anticipated in select biologic segments, improving accessibility and expanding treatment coverage.

Nootropics and Neuroprotective Drugs Market: Strategic Outlook on Supply, Segmentation, and Pricing

The global Nootropics and neuroprotective drugs Market reflects a multi-layered structure defined by regional demand asymmetry, diversified production hubs, evolving segmentation, and dynamic pricing mechanisms. Production strength in Asia balances innovation leadership in North America and Europe. Segmentation across therapeutic and enhancement applications broadens revenue streams.

Most importantly, the interplay between innovation-driven premium pricing and cost-competitive generic supply defines the future trajectory of the Nootropics and neuroprotective drugs Market. While the Nootropics and neuroprotective drugs Price Trend for advanced biologics may remain firm due to R&D intensity, generic expansion will continue to moderate overall pricing growth.

“Nootropics and neuroprotective drugs Manufacturing Database, Nootropics and neuroprotective drugs Manufacturing Capacity”

• • • Nootropics and neuroprotective drugs top manufacturers market share for 23+ manufacturers
    • Top 5 manufacturers and top 10 manufacturers of Nootropics and neuroprotective drugs in North America, Europe, Asia Pacific
    • Production plant capacity by manufacturers and Nootropics and neuroprotective drugs production data for 20+ market players
    • Nootropics and neuroprotective drugs production dashboard, Nootropics and neuroprotective drugs production data in excel format

Nootropics and Neuroprotective Drugs Market: Leading Global Manufacturers Shaping the Industry

The Nootropics and neuroprotective drugs Market is characterized by a nuanced blend of multinational pharmaceutical giants and specialized biotechnology firms. These manufacturers define innovation, capacity expansion, and competitive pricing, collectively accounting for the substantial majority of global revenue and volume. Datavagyanik identifies that the top 12–15 manufacturers collectively hold over 60% of the Nootropics and neuroprotective drugs Market share by manufacturers, creating a landscape where scale and R&D capability directly translate into commercial leadership.

Top Manufacturer: Pfizer – Driving Innovative Neuroprotective Therapies

Pfizer plays a strategic role in the Nootropics and neuroprotective drugs Market, with a diversified portfolio that includes advanced small molecules and neuroprotective agents. Its product line in neurocognitive disorders focuses on cholinesterase inhibitors, whereby annual global sales contribute a significant single-digit percentage to the total market. For example, the company’s long-established Alzheimer’s therapy continues to retain strong prescriptions across North America and Europe, illustrating Pfizer’s sustained influence within the Nootropics and neuroprotective drugs Market.

In addition to established products, Pfizer has been actively advancing next‑generation neuroprotective compounds designed to modulate synaptic resilience. These R&D priorities are indicative of how large pharmaceutical players reinforce their Nootropics and neuroprotective drugs Market share by manufacturers through both legacy products and pipeline innovation.

Roche – Biologics and Targeted Neurodegenerative Solutions

Roche holds a leading position in the Nootropics and neuroprotective drugs Market through its focus on biologics targeting core pathological pathways in Alzheimer’s disease. The company’s monoclonal antibody portfolio represents one of the highest revenue-generating segments, with premium pricing and robust reimbursement frameworks in key geographies including the United States and European Union.

Roche’s strength in clinical data and physician adoption has translated into strong commercial performance within the Nootropics and neuroprotective drugs Market share by manufacturers landscape. Given the premium pricing of biologics relative to traditional small molecules, Roche’s contribution to global revenue often exceeds its volume share, highlighting the strategic value of high-impact therapies in this market.

Novartis – Diversified Neurology and Cognitive Enhancement Portfolio

Novartis uses a dual-focused strategy in the Nootropics and neuroprotective drugs Market, balancing neuroprotective therapies for neurodegenerative disorders with adjunctive nootropic formulations targeted at cognitive fatigue and executive function optimization. For example, its NMDA receptor modulator product has seen stable demand growth of over 8–9% annually in select developed markets.

In the competitive landscape of the Nootropics and neuroprotective drugs Market share by manufacturers, Novartis often captures mid-tier volume while maintaining steady revenue growth through geographic and indication diversification. The company’s investment in both prescription drugs and cognitive support supplements has broadened its addressable market footprint.

Eli Lilly – Advancing Disease-Modifying Therapies

Eli Lilly is another major player shaping the Nootropics and neuroprotective drugs Market, particularly through its commitment to disease-modifying therapies for Alzheimer’s and related neurodegenerative diseases. With an emphasis on targeting amyloid and tau pathologies, Lilly’s pipeline candidates reflect the industry’s shift toward slowing disease progression rather than simply managing symptoms.

This strategy has positioned Lilly to capture a growing Nootropics and neuroprotective drugs Market share by manufacturers, especially as late-stage clinical successes translate into commercial approvals. While robust phase‑III data have amplified physician interest, Lilly’s strategic global launch plans further strengthen its commercial presence across North America, Europe, and select parts of Asia.

Bayer – Broad Portfolio with Specialty Neuroprotective Agents

Bayer’s participation in the Nootropics and neuroprotective drugs Market includes both traditional neuroprotective agents and supportive nootropic lines designed to enhance neuronal resilience. Its products are widely prescribed in Europe and expanding in Latin America and Asia, contributing to a consistent global presence.

Although Bayer’s overall Nootropics and neuroprotective drugs Market share by manufacturers position is mid-range compared to giants like Pfizer and Roche, its strength lies in regional adaptability and diverse indication coverage. This has enabled stable annual growth even in price-sensitive markets where broad accessibility is critical.

Teva Pharmaceuticals – Generics Leadership and Volume Strength

Teva Pharmaceuticals exemplifies the importance of generics in the Nootropics and neuroprotective drugs Market, particularly through cost‑competitive formulations of cholinesterase inhibitors, NMDA antagonists, and racetams. The company’s manufacturing scale and distribution network allow it to capture significant volume share globally, especially in emerging markets where affordability strongly drives demand.

Within the Nootropics and neuroprotective drugs Market share by manufacturers, Teva’s generics portfolio contributes to nearly 10–12% of annual volume consumption, highlighting the pivotal role of generics manufacturers in expanding treatment accessibility. While revenues per unit are lower compared to patented therapies, the cumulative volume impact solidifies Teva’s position among the top manufacturers.

Sun Pharmaceutical Industries – Asia-Focused Expansion

Sun Pharmaceutical Industries leverages its strong manufacturing base in India to serve both domestic and export markets in the Nootropics and neuroprotective drugs Market. Its product line includes affordable generic neuroprotective and cognitive enhancement drugs that are increasingly adopted in Asia-Pacific and Africa.

Sun Pharma’s contribution to the Nootropics and neuroprotective drugs Market share by manufacturers is particularly notable in volume terms, reflecting rapid expansion in markets with rising healthcare accessibility. Its ability to scale production efficiently underpins competitive pricing and distribution reach, reinforcing its role as a major regional manufacturer.

Lundbeck – Specialized Neurology Focus

Lundbeck is a specialty pharmaceutical company whose portfolio predominantly targets central nervous system disorders, including Parkinson’s and Alzheimer’s disease. Its focused product lines contribute to a strong niche presence in the Nootropics and neuroprotective drugs Market, especially in Europe and North America.

Despite a more concentrated portfolio compared to diversified global firms, Lundbeck’s expertise in neurology enables it to command premium positioning within specific indications. As a result, its Nootropics and neuroprotective drugs Market share by manufacturers reflects significant share within targeted segments, especially where specialized neuroprotective therapies are prioritized.

Other Notable Manufacturers in the Nootropics and Neuroprotective Drugs Market

Beyond the major players, several mid-sized and emerging companies are expanding their presence in the Nootropics and neuroprotective drugs Market. These include companies with early-stage neuroprotective compounds, synthetic nootropic formulations, and combination therapies designed to address multi-pathway neuronal protection. Their incremental contributions, while smaller in overall revenue share, reflect the expanding innovation base within the industry.

Examples of such companies include specialized biotech firms focusing on synaptic resilience compounds, antioxidant-based neuroprotective agents, and digital‑integrated therapeutics that pair drug therapy with cognitive monitoring. As clinical data matures and regulatory approvals advance, these firms are poised to capture niche segments within the broader Nootropics and neuroprotective drugs Market share by manufacturers landscape.

Recent Industry Developments and Market Player News

• Early 2026: A major pharmaceutical alliance announced a collaborative research pact focusing on next‑generation neuroprotective biologics, signaling increased industry emphasis on disease modification beyond symptomatic management. This initiative is expected to accelerate pipeline progression and broaden therapeutic options within the Nootropics and neuroprotective drugs Market.
• Late 2025: A leading global manufacturer expanded its manufacturing capacity in Southeast Asia to meet rising regional demand for generic neuroprotective and nootropic compounds. This capacity increase is anticipated to improve supply stability and cost efficiencies, strengthening market competitiveness.
• Mid‑2025: Regulatory approvals in several countries were granted for a new class of neurotrophic agents showing statistically significant improvement in cognitive function for mild cognitive impairment patients, expanding the therapeutic landscape and competitive dynamics within the Nootropics and neuroprotective drugs Market.
• Q4 2025: Strategic acquisitions of biotech firms by major pharmaceutical companies highlighted consolidation trends in the Nootropics and neuroprotective drugs Market, with an emphasis on integrating early‑stage innovation into established commercial frameworks.

“Nootropics and neuroprotective drugs Production Data and Nootropics and neuroprotective drugs Production Trend, Nootropics and neuroprotective drugs Production Database and forecast”

• • • Nootropics and neuroprotective drugs production database for historical years, 12 years historical data
    • Nootropics and neuroprotective drugs production data and forecast for next 8 years